Hyoscyamine is not FDA approved because most hyoscyamine products were already being sold before Congress required drugmakers to prove effectiveness in 1962, and their manufacturers never submitted the clinical trial data needed to earn approval under the modern standard. The drug remains widely prescribed, but many versions on pharmacy shelves sit outside the FDA’s formal review system, which affects how they’re labeled, whether insurance covers them, and what safety oversight applies.
The 1962 Law That Left Hyoscyamine Behind
Before 1962, a manufacturer only had to show a drug was safe to put it on the market. The Kefauver-Harris Amendments changed that by adding an effectiveness requirement: every new drug now needed substantial evidence that it actually worked.1U.S. Government Publishing Office. Public Law 87-781 – Drug Amendments of 1962 That left thousands of older drugs in limbo. They had cleared the old safety-only bar but had never been tested for effectiveness through controlled clinical trials.
To sort out the backlog, the FDA launched the Drug Efficacy Study Implementation (DESI) program, contracting with the National Academy of Sciences to evaluate more than 3,400 drugs that had been approved for safety alone between 1938 and 1962.2U.S. Food and Drug Administration. Drug Efficacy Study Implementation (DESI) The review also swept in a larger number of products that had entered the market without any FDA approval at all, sold as identical or similar to those older safety-approved drugs. Hyoscyamine, a belladonna alkaloid used for centuries as an antispasmodic, fell squarely into that group. DESI reviews of anticholinergic drug combinations found several lacked substantial evidence of effectiveness for gastrointestinal disorders, raising questions about the class as a whole.
Why Manufacturers Never Submitted the Data
DESI was supposed to be temporary. It dragged on for decades. Many manufacturers were told their products needed modern efficacy data and simply never submitted it. The reasons were largely economic. Running a full clinical trial program costs hundreds of millions of dollars and takes years, and hyoscyamine is a cheap, off-patent compound. Some companies calculated that the return on that investment wasn’t there. Others assumed the FDA would never get around to enforcing the requirement.
They weren’t entirely wrong. Federal law is clear that no new drug can be introduced into interstate commerce without an effective approval,3Office of the Law Revision Counsel. 21 U.S. Code 355 – New Drugs but “illegal to sell” and “removed from the market” are two different things. The FDA uses a risk-based enforcement approach, prioritizing action against unapproved drugs that pose the greatest threat to public health rather than pulling everything at once and disrupting patient access.4Food and Drug Administration. Compliance Program Manual – Unapproved New Drugs The agency’s priorities focus on drugs with safety risks, drugs lacking evidence of effectiveness, health fraud products, and drugs that directly compete with an approved version of the same medication. Since 2006, the FDA has actively worked to remove unapproved drugs from the market, and manufacturers still selling them do so knowing enforcement action can come at any time and without prior notice.5U.S. Food and Drug Administration. Unapproved Drugs
Some Hyoscyamine Products Are Approved
This is where things get confusing at the pharmacy counter. Some newer formulations of hyoscyamine have gone through the full New Drug Application process and are legitimately approved. An approved and an unapproved version of the same active ingredient can sit side by side on the same shelf. The lack of approval doesn’t prevent a pharmacist from dispensing an unapproved product or a doctor from prescribing it. What it does mean is that the unapproved version was never held to the manufacturing, labeling, and testing standards that modern drug law requires.
What the Missing Approval Means for Safety and Labeling
The gap is not just paperwork. Unapproved drugs may not meet current standards for manufacturing quality, and their labeling often hasn’t been updated to reflect modern safety data.4Food and Drug Administration. Compliance Program Manual – Unapproved New Drugs That matters for hyoscyamine because of its anticholinergic properties, which carry documented risks.
Hyoscyamine works by blocking acetylcholine, a chemical messenger involved in muscle contractions and various body functions. This mechanism relieves spasms but also produces side effects including dry mouth, blurred vision, constipation, decreased sweating, urinary retention, dizziness, and drowsiness. More serious reactions can include confusion, hallucinations, memory problems, and rapid heartbeat. Because the drug decreases sweating, people taking it face a higher risk of heat stroke during exercise or hot weather.
The risks are most acute for older adults. The American Geriatrics Society’s Beers Criteria, the standard reference for medications that are potentially inappropriate in elderly patients, lists hyoscyamine as a drug to avoid, describing it as “highly anticholinergic” with “uncertain effectiveness.” Cumulative exposure to anticholinergic drugs is associated with increased risk of falls, delirium, and dementia. For older patients with existing cognitive impairment, these drugs can worsen symptoms. For those with enlarged prostates or urinary problems, hyoscyamine can cause urinary retention.
An approved drug carries labeling that reflects this kind of evidence, updated through the FDA’s ongoing post-market review. Unapproved products have no such obligation, and their package inserts may be years or decades behind current medical knowledge on drug interactions, contraindications, and vulnerable populations.
Insurance Coverage Can Be a Problem
Unapproved status also creates coverage headaches. Medicaid generally requires that a drug be FDA-approved to qualify for federal reimbursement, with narrow exceptions for items like prescription prenatal vitamins and drugs prescribed during shortages.6U.S. Department of Health and Human Services Office of Inspector General. One Percent of Drugs With Medicaid Reimbursement Were Not FDA-Approved Patients with private insurance may also face coverage denials or higher copays when a plan’s formulary excludes unapproved products, though practices vary widely among insurers.
How to Check Whether Your Hyoscyamine Is Approved
The FDA runs two free online databases you can search. Drugs@FDA lists most prescription and over-the-counter products approved since 1939, and the Orange Book contains drugs approved under New Drug Applications and Abbreviated New Drug Applications.7U.S. Food and Drug Administration. How Do I Find Out if a Drug Is Approved Search for your specific product by name. If it doesn’t appear, that’s a strong indicator it lacks formal approval.
You can also call the FDA’s drug information line at 1-888-463-6332 or email druginfo@fda.hhs.gov. Your pharmacist should be able to tell you whether the specific manufacturer’s product they dispensed holds an approved NDA.
What to Do If Yours Is Unapproved
Don’t stop taking it abruptly. Talk to your doctor about whether an approved version of hyoscyamine exists in the formulation you need, or whether an alternative medication would work. The conversation is worth having, particularly if you’re over 65, if you have cognitive impairment or urinary problems, or if you’re taking other medications with anticholinergic effects. Hyoscyamine can be effective for certain conditions, but you’re entitled to know exactly what you’re taking and what regulatory review stands behind it.